Mata, Melinda
Gottschalk, Stephen http://orcid.org/0000-0003-3991-7468
Article History
First Online: 23 February 2019
Compliance with Ethical Standards
:
: The authors were supported by US National Institutes of Health (NIH) 1R01CA173750 and 1R01NS106379-01A1, and Cancer Prevention and Research Institute of Texas (CPRIT) grant RP101335.
: Melinda Mata has no conflict of interest; she is currently an employee of Immatics US, Inc. Stephen Gottschalk has patents and patent applications in the field of T cell therapy and gene therapy for cancer, is a consultant of ViraCyte, LLC, a member of the data safety monitoring board of Immatics US, Inc., and received research funding from Tessa Therapeutics LTD.
Free to read: This content has been made available to all.